Drug Database
AR

artesunate (artesunate, Amivas)

✓ Approved

Amivas · 小分子 · 小分子

什么是 artesunate?

artesunate 是一种小分子,由Amivas研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名artesunate, Amivas
公司Amivas
药物类别小分子
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

artesunate 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsPlasmodium malariae infection✓ Approved
Infections and infestationsCytomegalovirus infectionPreclinical

相关研究文献

PubMedActa tropica2026-11-18

Molecular detection and therapeutic management of Babesia gibsoni and Ehrlichia canis co-infection in dogs along with characterisation of the pathogens.

Pati Mirashree M, Biswal Sangram S, Mishra Smruti Ranjan SR, Dehuri Manaswini M et al.

Tick-borne hemoparasitic infections constitute an important cause of clinical morbidity in dogs, particularly in endemic regions where vector exposure facilitates concurrent transmission of multiple pathogens. This study aimed to molecularly detect and characterise Babesia gibsoni and Ehrlichia canis co-infection in dogs, assess associated clinico-hemato-biochemical alterations, and evaluate the therapeutic efficacy of artesunate-atovaquone-doxycycline (AAD) regimen. A total of 184 clinically suspected dogs were screened by internally controlled multiplex PCR, and positive cases were further confirmed by species-specific real-time quantitative PCR (qPCR) and sequencing. The prevalence of B. gibsoni and E. canis co-infection was 7.6% (14/184). Eight infected dogs were treated with AAD protocol and the relative abundance of parasite target DNA was assessed on days 0, 10, 28, and 90 using relative quantification (RQ) qPCR targeting B. gibsoni 18S rRNA and E. canis VirB9 gene that has been normalized to canine β-actin by the 2-ΔΔCt method. Infected dogs exhibited normocytic-normochromic anaemia, thrombocytopenia, hypoproteinaemia, hyperglobulinaemia, hyperbilirubinemia, azotaemia, high serum alkaline phosphatase and aspartate transaminase level whereas, mean creatinine level were found within normal physiological range. Following AAD therapy, dogs showed rapid clinical recovery, with significant improvement in hemato-biochemical parameters by day 90. Significant reduction in parasite DNA load was noted, reflected by rising Ct values and progressively declining log RQ values for both pathogens. These findings indicated that the AAD regimen showed potential effectiveness against canine B. gibsoni and E. canis co-infection, however this preliminary clinical observation may be validated through further controlled trials.

PMID 43051342
阅读全文 →
PubMedTropical medicine and health2026-11-17

Survival following 14% Plasmodium falciparum hyperparasitaemia: cerebral malaria and anaemic heart failure in a Nigerian toddler.

Unuane Amos E AE, Adedosu Nelson A NA, Obia Finesse C FC, Jegede Tolulope O TO et al.

Malaria remains a leading cause of mortality amongst children under five in sub-Saharan Africa. Complicated Plasmodium falciparum malaria frequently presents with multiple life-threatening sequelae, including cerebral malaria, profound anaemia, and hyperparasitaemia. Although parasite densities exceeding 10% are independently associated with high mortality, achieving full recovery in a young child presenting with simultaneous extreme parasitaemia, deep coma, and severe malarial anaemia remains exceptionally noteworthy. We report the case of a 20-month-old male from Akoko, Ondo State, Nigeria, who presented with a five-day history of fever, cough, and diarrhoea, progressing to unconsciousness. Clinical examination revealed a Blantyre Coma Scale of 2/5, profound pallor, tachycardia (158 bpm), and tender hepatomegaly. Laboratory investigations confirmed an extreme 14% P. falciparum parasitaemia and a life-threatening packed cell volume of 8%. Cerebrospinal fluid analysis ruled out bacterial meningitis though an elevated protein level (71 mg/dL) supported the diagnosis of cerebral malaria. The patient was stabilised in the cardiac position to optimise venous return and alleviate signs of incipient heart failure, and was initiated on a multi-modal therapeutic regimen. Antimalarial therapy was commenced with intravenous artesunate (3 mg/kg), supported by two sessions of sedimented red blood cell transfusions and empiric IV Ceftriaxone. By the fourth day of treatment, the child regained full consciousness and was transitioned to oral artemether-lumefantrine. The patient was discharged in a stable condition on day seven with a recovered packed cell volume of 35%. This case highlights the critical importance of the "24-h window" in treating severe malaria. The successful outcome confirms the efficacy of intravenous artesunate and the necessity of aggressive supportive care-including blood transfusion-in managing the severe triad of hyperparasitaemia, cerebral sequestration, and severe anaemia in paediatric patients within endemic regions. This report emphasises the need for public health initiatives that educate caregivers on the early recognition of malaria symptoms to facilitate prompt care. Furthermore, it reaffirms that urgent microscopic evaluation remains the gold standard for the immediate diagnosis of hyperparasitaemic cases in resource-limited settings.

PMID 43040445
阅读全文 →
PubMedChemMedChem2026-11-16

Artesunate Derivatives as Anticancer Agents: Hybrid Designs and Emerging Therapeutic Strategies.

Selaković Milica M, Koračak Ljiljana L, Ajdačić Vladimir V, Nikolić Andrea M AM et al.

Artesunate is a semisynthetic derivative of the natural product artemisinin, isolated from Artemisia annua and characterized by the biologically important endoperoxide bridge. Beyond its established use in malaria treatment, in recent decades, artesunate has attracted growing research interest as an anticancer agent. Despite encouraging preclinical results, clinical studies demonstrated only modest efficacy when artesunate was used as a single compound, due to its low bioavailability, toxicity, and unfavorable side effects. For this reason, artesunate derivatization has attracted significant attention, as the resulting derivatives often exhibit superior anticancer activity in both in vitro and in vivo studies compared with artesunate alone. This review offers a comprehensive overview of reported artesunate derivatives, structured into sections based on the type of molecule employed for derivatization and highlights the expanding research on their anticancer activity. Currently emerging strategies that include hybridization and nanocarrier-based delivery systems which may accelerate the clinical translation of artesunate derivatives and harness their potential in anticancer drug discovery are also discussed. While significant progress has been made, a lot of the research field still remains underexplored.

PMID 43039867
阅读全文 →
PubMedJournal of pharmaceutical analysis2026-11-15

Targeting SEC23A: Artesunate's dual pathway approach to reversing gastric metaplasia.

Hu Qichao Q, Wu Feng F, Zhang Yuanhao Y, Zeng Lingshun L et al.

Artesunate (ART) is a promising multi-target drug, yet its efficacy and mechanism against intestinal metaplasia (IM)/spasmolytic polypeptide-expressing metaplasia (SPEM), a key precancerous gastric lesion with no effective therapy, remain unexplored. This work presented that ART reversed SPEM and IM progression in mice, selectively impairing IM cell viability via inducing paraptosis. Mechanistically, ART triggered paraptosis through dual pathways, involving reactive oxygen species (ROS)-dependent c-Jun N-terminal kinase (JNK)/P38 mitogen-activated protein kinase (MAPK) activation and ROS-independent endoplasmic reticulum (ER) stress via direct SEC23 homolog A (SEC23A) binding. ART disrupted SEC23A-SEC24 homolog A (SEC24A) dimer formation, inducing ER stress via promoting K63-linked ubiquitination and P62-mediated autophagic degradation of SEC23A. Moreover, its efficacy was confirmed in human-derived IM organoids, showing reduced growth, SEC23A degradation, and MAPK/ER stress activation. Taken together, ART alleviates gastric precancerous lesions by selectively inducing paraptosis through ROS-dependent JNK/P38 MAPK activation and SEC23A-targeted ER stress via coatomer protein complex II (COPII) disruption and autophagic degradation.

PMID 43034754
阅读全文 →
PubMedFuture medicinal chemistry2026-11-11

Pyrimidine-based hybrids as modulators of P-glycoprotein-mediated multidrug resistance: lipophilicity and SAR perspectives.

Šegan Sandra S, Mosić Mirjana M, Pešić Milica M

An important obstacle to efficient anticancer therapy is multidrug resistance (MDR) mediated by efflux transporters, particularly P-glycoprotein (P-gp/ABCB1). Pyrimidine-based hybrids comprise different scaffolds with favorable physicochemical profiles that can modulate transporter activity. This review presents a descriptor-oriented analysis of the lipophilicity, polarity, amphiphilicity, and conformational flexibility across the principal structural architectures of pyrimidine hybrids (linked, fused, and natural product-derived), with conjugation considered as a cross-cutting structural feature to assess their influence on membrane permeability, intracellular accumulation, and P-gp modulation.Particular emphasis is placed on integrating experimentally determined and computationally predicted lipophilicity descriptors with structure-activity relationships (SAR) to demonstrate how scaffold architecture and physicochemical properties collectively influence MDR-related biological responses.This relationship is illustrated by studies on pyrimidine-hydrazone, pyrazolo[3,4-d]pyrimidine, oxazolo[5,4-d]pyrimidine, and artesunate-pyrimidine hybrids, which collectively demonstrate that balanced lipophilicity and amphiphilicity are key determinants of P-gp modulation.Collectively, SAR analyses, molecular docking, molecular dynamics simulations, and experimental studies indicate that hydrophobic and amphiphilic balance, rather than hydrogen-bonding capacity alone, govern P-gp recognition. By integrating structural, physicochemical, and biological findings, this review provides a framework for the rational optimization of pyrimidine-based hybrids to achieve more effective P-gp modulation and improved anticancer drug design.

PMID 43015123
阅读全文 →
PubMedMalaria journal2026-11-10

Evaluation of adherence to WHO guidelines for prescription of artemisinin combination therapy (ACTs) and artesunate in Kilifi County, Kenya.

Ngala Jonathan Chome JC

Malaria is a vector-borne disease caused by a protozoan parasite in the genus Plasmodium. The parasite is transmitted by female mosquitoes in the genus Anopheles. The disease is common within the tropics, especially in sub-Saharan Africa. The major early clinical features are fever accompanied by headache, joint pains, malaise, vomiting, and diarrhoea. These symptoms are some instances used as a diagnosis for malaria infection without confirmatory laboratory tests; followed by prescription of first-line antimalarials, mainly artemisinin combination therapy (ACTs). This trend of prescribing antimalarials to patients presenting with malaria-like symptoms without confirmatory laboratory tests is contrary to World Health Organization's (WHO) recommended guidelines. Such practices pose a great risk for suboptimal medication, development of resistance against the drugs, treatment failure, and increased morbidity and mortality. Therefore, this study was conducted to evaluate adherence to WHO-recommended guidelines for prescription of ACTs and artesunate. This was a cross-sectional study in four health facilities in Kilifi County for a period of one year. 9,940 participants consented to inclusion in the survey. Pre- and post-ACTs/artesunate prescription data was captured using standardized case record forms. Out of the 9,940 patients, 80.4% had confirmed malaria infections, out of which 60% (n = 4,795) were males. 48% (n = 3,836), of the malaria cases were from rural areas. 17% (n = 1,359), of the positive cases were severe malaria, with 92% (n = 1,251), being in children under the age of 15 years old. Adherence to WHO guidelines for diagnosis of malaria was, at 99% (9,841/9,940), with Rapid diagnostic test as the most used technique, at 74% (n = 7,356). Adherence to WHO guidelines for prescription of ACTs was, at 48% (3,184/6,633), with Coartem as the most prescribed ACT, at 98% (n = 6,436). Adherence to WHO guidelines for prescription and administration of artesunate was, at 82% (1,114/1,359). Artesunate injection was administered to all cases of severe malaria. Adherence to WHO guidelines for prescription of ACTs and artesunate in Kilifi County had improved substantially, although there exists a room for improvement, especially on instructions on how to take the ACT medications following hospital discharge. Therefore, stakeholders, especially the county's ministry of health, should put more effort into further improvement through seminars, short training courses, and workshops to reduce the disease burden and prevent the likelihood of the development of ACTs and artesunate resistance by malaria parasites in the region.

PMID 43004342
阅读全文 →

注册免费账户还可查看另外 4242 篇文献

免费注册查看全部文献 →

了解更多artesunate